Abivax SA (ABVX) | Stock Overview & Key Data
Abivax SA | Large-cap | Healthcare
Abivax SA | Large-cap | Healthcare
Abivax SA Performance Comparison
Stock Range
Today's Range
Low: €60.00
High: €62.70
on August 4, 2025
52 Week Range
Low: €4.51
High: €64.40
on April 9, 2025
on July 31, 2025
All-Time High: €64.40 on July 31, 2025
Explore how other French stocks compare to their 52-week ranges: View FR Market 52-Week Insights
Key Statistics
Market Cap
€4.6B
EPS
-2.95
P/E Ratio (TTM)
-22.00
Forward P/E
-41.63
P/B Ratio
-588.41
PEG Ratio
-41.63
Div. Yield
N/A
ROE
-196.12%
Beta
1.534
Debt to Equity
-16.16
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-4,865.98%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-48.60%
Return on Equity (TTM)
-196.12%
EBITDA
€-174.4M
Net Income (TTM)
€-185.7M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€0.17
Quarterly Revenue Growth (YoY)
-17.40%
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Abivax SA ABVX | 4.60B Large-cap | 7.37% | 827.27% | 842.99% | 947.95% | 740.66% | 460.44% | 686.63% | 211.61% |
| Valneva SE VLA | 555.77M Mid-cap | -3.70% | 31.65% | 7.22% | 16.85% | 35.06% | -0.95% | -67.93% | -42.75% |
| Medincell S.A MEDCL | 537.65M Mid-cap | -7.19% | -3.58% | 2.58% | 1.66% | -9.46% | 4.20% | 208.35% | 115.18% |
| BNP Paribas Easy BLUE | 463.10M Mid-cap | -2.20% | -0.89% | 0.52% | -5.19% | -5.19% | -2.63% | 1.50% | 49.76% |
| Inventiva S.A IVA | 387.35M Mid-cap | 1.09% | 7.72% | -13.89% | 20.26% | 32.23% | 29.77% | -38.95% | -70.82% |
| Nanobiotix NANO | 278.74M Mid-cap | 2.26% | 43.41% | 92.79% | 73.45% | 91.53% | 27.00% | 54.74% | -16.12% |
Ownership & Short Interest
Insider Ownership
0.67%
Institutional Ownership
41.36%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
572K
Average 90-Day Volume
274K
Abivax SA Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Abivax SA would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ABVX's 52-week high and low?
- In the last 52 weeks, Abivax SA reached a high of €64.40 (on July 31, 2025) and a low of €4.51 (on April 9, 2025).
- What is the market cap and P/E ratio for ABVX?
- Curious about Abivax SA's size and valuation? Its market capitalization stands at 4.60B. When it comes to valuation, the P/E ratio (trailing twelve months) is -22.00, and the forward P/E (looking ahead) is -41.63.
- Does ABVX pay dividends? If so, what's the yield?
- As for dividends, Abivax SA isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Abivax SA's main competitors or similar companies to consider before investing?
When looking at Abivax SA, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Valneva SE
VLA555.77M Healthcare Biotechnology -0.95% -67.93% Medincell S.A
MEDCL537.65M Healthcare Biotechnology 4.20% 208.35% BNP Paribas Easy
BLUE463.10M Healthcare Biotechnology -2.63% 1.50% Inventiva S.A
IVA387.35M Healthcare Biotechnology 29.77% -38.95% Nanobiotix
NANO278.74M Healthcare Biotechnology 27.00% 54.74% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Abivax SA? (e.g., ROE, Debt/Equity)
- To get a sense of Abivax SA's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -196.12%, the Debt to Equity ratio from the most recent quarter is -16.16, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for ABVX?
- Looking at Abivax SA's growth, its revenue over the trailing twelve months (TTM) was €11M. Compared to the same quarter last year (YoY), quarterly revenue grew by -17.40%, and quarterly earnings saw a YoY growth of N/A.
- How much of ABVX stock is held by insiders and institutions?
- Wondering who owns Abivax SA stock? Company insiders (like executives and directors) hold about 0.67% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 41.36%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.